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2 
Abstract 1 
The fimbriae of Bordetella pertussis are required for colonisation of the human respiratory tract. 2 
Two serologically distinct fimbrial subunits, Fim2 and Fim3, having been considered important 3 
vaccine components for many years, are included in the Sanofi Pasteur 5-component acellular 4 
pertussis vaccine, and the World Health Organisation recommends the inclusion of strains 5 
expressing both fimbrial serotypes in whole cell pertussis vaccines. Each of the fimbrial major 6 
subunit genes, fim2, fim3, and also fimX, has a promoter poly(C) tract upstream of its í10 box. Such 7 
monotonic DNA elements are susceptible to changes in length via slipped-strand mispairing in vitro 8 
and in vivo, which can potentially cause on/off switching of genes at every cell division. Here we 9 
describe intra±culture variability in poly(C) tract lengths and in the resulting fimbrial phenotypes in 10 
22 recent United Kingdom B. pertussis isolates. Owing to the highly plastic nature of the fimbrial 11 
promoters, we used the same cultures for both genome sequencing and flow cytometry. Individual 12 
cultures of B. pertussis each contained multiple fimbrial serotypes and multiple different fimbrial 13 
promoter poly(C) tract lengths, which supports earlier serological evidence that B. pertussis 14 
expresses both serotypes during infection.  15 
3 
Introduction 1 
Bordetella pertussis causes whooping cough and this continues to be a public health problem 2 
despite high vaccine coverage. Rates of pertussis disease have increased in many countries in recent 3 
years and this is thought to be due to a combination of strain evolution (Mooi et al., 2013) and 4 
faster waning immunity provided by acellular pertussis (aP) vaccines compared to whole cell 5 
pertussis vaccines (wP) used previously (Tartof et al., 2013). In addition, evidence from a baboon 6 
model of pertussis indicates that acellular vaccines may be less effective than whole cell vaccines at 7 
preventing acquisition and transmission of the organism (Warfel et al., 2014). It is important for the 8 
pathogenesis of pertussis disease that B. pertussis is able to adhere to the mucosal surface in the 9 
upper respiratory tract via a number of adhesins including filamentous haemagglutinin, pertactin 10 
and fimbriae (Mattoo & Cherry, 2005). B. pertussis expresses two serologically distinct fimbriae 11 
which are composed of either Fim2 or Fim3 subunits (22.5 and 22.0 kDa respectively). Subtypes of 12 
Fim2 (fim2-1 and fim2-2) and Fim3 (fim3-1, fim3-2 and fim3-3) have also been described (Packard 13 
et al., 2004; Tsang et al., 2004). Both Fim2 and Fim3 subunits are assembled in a coil to produce 14 
long filaments on the surface of the bacteria (Heck et al., 1996). Fimbriae (co-purified Fim2/3) have 15 
been shown to be protective antigens in mouse models of pertussis (Heininger et al., 1998; 16 
Robinson et al., 1989a) and are components of an acellular vaccine which showed high efficacy in 17 
phase III clinical trials (Gustafsson et al., 1996; Olin, 1997). Household contact studies performed 18 
during these trials showed a correlation between antibody responses to fimbriae and protection 19 
against disease (Cherry et al., 1998; Storsaeter et al., 1998). 20 
Expression of many B. pertussis virulence-related genes, including fim2 and fim3, is regulated by 21 
the BvgA/S two-component system. (Decker et al., 2012). Transcription of fim3 is proposed to 22 
occur when a dimer of phosphorylated BvgA is bound to the fim3 SURPRWHU¶V í35 region at the 23 
same time as region 4 of the RNA polymerase 180 subunit and the C-terminal domain of an RNA 24 
polymerase . subunit (Decker et al., 2011). Poly(C) tracts, and homopolymeric tracts generally, are 25 
4 
under-represented in the B. pertussis chromosome (Coenye & Vandamme, 2005), and the possibility 1 
of rapid antigenic variation via slipped-strand mispairing at these sites has received limited 2 
attention. However, each of the fim genes possesses a poly(C) tract between its í35 and í10 3 
promoter regions. Transcription-permissive lengths for the fimbrial poly(C) tracts have been 4 
determined (Willems et al., 1990; Chen et al., 2010), but the frequency of slipped-strand mispairing 5 
within them has not been previously described. The fimbrial poly(C) tracts of B. pertussis have a 6 
notable counterpart in the porA promoter of Neisseria meningitidis, where altered transcription 7 
levels, caused by changes in the length of a poly(G) tract between the í35 and í10 regions, can 8 
facilitate the evasion of bactericidal anti-PorA antibodies (Tauseef et al., 2013).  9 
In this study, we have analysed whole genome sequencing reads from a panel of 96 B. pertussis 10 
strains isolated in the United Kingdom between 1920 and 2012, and shown that cultures of B. 11 
pertussis contain multiple subpopulations with differing fimbrial poly(C) tract lengths. In addition, 12 
we preserved aliquots from 22 of the cultures used for genome sequencing and have analysed Fim2 13 
and Fim3 expression on individual bacteria using labelled anti-Fim2 and anti-Fim3 monoclonal 14 
antibodies in two-colour flow cytometry. This demonstrated that bacteria expressing Fim2 and/or 15 
Fim3 are present in cultures previously shown by standard slide agglutination methods to express 16 
only one fimbrial serotype. Thus, these data show that expression of Fim2 and Fim3 by B. pertussis 17 
is more flexible than generally acknowledged, and this flexibility may help to explain the rapid 18 
shifts in predominant serotype observed in many countries. 19 
Materials and methods 20 
Bacteria 21 
Ninety-six B. pertussis isolates UK001 to UK06, UK008 to UK011, UK014 to UK018, UK020 to 22 
UK100 were obtained from the Respiratory and Vaccine Preventable Bacteria Reference Unit 23 
(RVPBRU), Public Health England (PHE) Colindale, London. The majority of these isolates (n = 24 
5 
87) were submitted by hospital laboratories as part of the enhanced surveillance of pertussis (Van 1 
Buynder et al., 1999). Additional isolates were previously obtained from the Wellcome Bacterial 2 
Collection, held by the National Collection of Type Cultures (NCTC) (n = 4); the NCTC (n = 2) and 3 
the former Centre for Applied Microbiology and Research, now PHE Porton Down, Salisbury (n = 4 
3) (Fry et al., 2001). 5 
Following culture for 48 to 72 h on blood charcoal agar (PHE Media Services, Colindale), B. 6 
pertussis isolates were serotyped using a slide agglutination assay with rabbit polyclonal antisera 7 
against antigens 1, 2, and 3 (89/596, 89/598, and 89/600, respectively; National Institute for 8 
Biological Standards and Controls, Potters Bar, United Kingdom). Antigen 1 (agglutinogen 1) is 9 
expressed by all isolates of B. pertussisWKXVWKHQRWDWLRQ)LPí)LP, Fim3 and Fim2,3 (Hallander 10 
et al., 2005) is used instead of the historical notation serotype 1, serotype 1,2 serotype 1,3 and 11 
serotype 1,2,3 (Robinson et al., 1989b) as previously described (Litt et al., 2009). The terms Fim 12 
aQG )LPí)LPí DUH XVed interchangeably in the text. Cultures for this study were grown on 13 
charcoal agar for 72h at 37oC. For flow cytometry analysis, bacteria were resuspended in PBS 14 
containing 1% formaldehyde and the OD600 nm adjusted to 2.0. 15 
Genome sequencing 16 
Genome sequencing of UK isolates UK001 to UK100 was performed at the Sanger Institute and 17 
detailed analysis of these sequences will be the subject of a paper in preparation. Briefly, paired-end 18 
libraries were prepared from genomic DNA, amplified with a KAPA HiFi library amplification kit 19 
(Kapa Biosystems Inc, Wilmington MA), and sequenced as 150 bp paired-end reads using a MiSeq 20 
desktop sequencer (Illumina Inc, San Diego, CA). The unassembled short reads are available in 21 
fastq.gz format from the 6DQJHU ,QVWLWXWH¶V IWS VLWH. Locations of the files are in Table S1 22 
(supplementary materials). Additional genome sequence files (non-UK isolates) are listed in Table 23 
S2 (supplementary materials). 24 
6 
Extraction of poly(C)-tract±spanning reads from fastq.gz files 1 
Each fastq.gz file was read with kseq_test, a minimal example program for the kseq.h fastq parser 2 
library (Li, 2011; Li, 2012). Output from kseq_test was piped into a script written in AWK (Aho et 3 
al., 1988), within which the sequence field of each Illumina read was put through two successive 4 
filters. 5 
The first filter compared each read to the set of all plausible fimbrial poly(C) tracts (6±20 base 6 
pairs) flanked by a minimal B. pertussis Tohama I±derived context (Parkhill et al., 2003). The 7 
search patterns used in this first filter are shown as regular expressions in Table 1. The fim2 regular 8 
expressions contain a [CT] character list, corresponding to the deoxythymidine that punctuates the 9 
poly(C) tract of B. pertussis Tohama. Three regular expressions are necessary to prevent fim3 and 10 
fimX sequences from being misidentified as each other. Reverse-complement patterns, not shown in 11 
Table 1, were also used, giving a total of 308 patterns upon evaluation of the regular expressions. 12 
Non-matching reads (including all reads ending within poly(C) tracts) were discarded, and exact 13 
matches were tested in the second filter. 14 
The second filter took the segments of each read outside the initial match, joined them and aligned 15 
the resulting chimaera to the equivalent joined 30 bp segments from B. pertussis Tohama I. For this 16 
alignment, EMBOSS needle (Rice et al., 2000) was used via AWK¶V getline. The alignment was 17 
forced to be local with respect to query and global with respect to reference (by invoking needle 18 
with an endweight, a zero end-open penalty and high gap open/extend penalties). Reads were given 19 
a positive plausibility score if this second filter resulted in a plausible alignment (aligned join-sites, 20 
 66.7 LGHQWLW\DFURVVESZKHUHIODQNLQJVHTXHQFHZDVDYDLODEOHRQERWKVLGHVRIWKHLQLWLDO21 
PDWFK LGHQWLW\DFURVVESZKHUHIODQNLQJVHTXHQFHZDVDYDLODEOHRQRQO\RQHVLGHRI22 
the initial match); otherwise reads were given a negative score. Each fastq record was reassembled 23 
7 
into a one-line tab-delimited format and augmented with gene name (fim2, fim3 or fimX), isolate 1 
name, fastq.gz file name and plausibility score. 2 
The kseq_test preprocessing step and the AWK/needle double filter were combined as a single 3 
Bourne shell script, and summary counts were extracted from the tab-delimited output using a 4 
second shell script (supplementary materials: MeasurePolyC.sh and 5 
FastqplusToTable.sh). The AWK script embedded in MeasurePolyC.sh induced a 6 
memory leak in GNU awk, but not in nawk or mawk. Arithmetic means and standard deviations 7 
(Table 3 and supplementary materials, CoverageStatsUKstrains.awk) were calculated 8 
using the Welford±Knuth algorithm (Welford, 1962; Knuth, 1997, pp. 231±232). 9 
Detection of Fim2 and Fim3 by flow cytometry 10 
200 µl of each suspension (OD600 = 0.1) of plate-grown bacteria was added to a well of a 96-well 11 
microtitre plate. The plate was centrifuged at 3060 × g for 5 min. and supernatant was removed. 12 
Fim2- and Fim3-specific monoclonal antibodies (06/124 and 06/128 respectively, obtained from the 13 
National Institute of Biological Standards and Control, UK) were bound to AlexaFluor 488 and 14 
Alexafluor 647, respectively, using a Zenon® Alexa Fluor® Mouse IgG1 Labelling Kit (Life 15 
Technologies, Paisley, UK). 100 µl of each antibody at a dilution of 1 in 5000 was added to each 16 
test well and pellets were resuspended. The plate was incubated at 25 °C with shaking, for 30 min. 17 
The plate was centrifuged as above and washed, and pellets were resuspended in 200 µl blocking 18 
buffer (PBS, 1 % BSA). Samples were analysed using a Beckman Coulter CyanADP flow 19 
cytometer, and Summit® software was used to calculate the median fluorescence of each 20 
fluorophore for each sample. Unstained bacterial cells were used to verify the absence of 21 
fluorophore-independent counts, which are minimised by the use of filter-sterilised buffers and 22 
sheath fluid and by the collection of 10,000 events per sample. 23 
8 
A gate was drawn to include the bacteria plus conjugate control (no antibody), resulting in a median 1 
fluorescence >20 being considered positive for Fim expression. To ascertain the percentage of 2 
bacterial cells expressing Fim2 or Fim3, AlexaFluor 488 fluorescence was plotted against 3 
AlexaFluor 647 fluorescence for each sample. Gates were drawn to enclose the negative control 4 
sample and used to determine the demarcation between a positive and negative result. This gate was 5 
then applied to all test samples, allowing the determination of the percentage of events, or 6 
individual bacteria, which were not fluorescent, singly positive for AlexaFluor 488, singly positive 7 
for AlexaFluor 647 or doubly positive for both Alexafluor 488 and Alexafluor 647, thereby 8 
determining the percentage of individual bacteria expressing Fim2, Fim3 or both Fim2 and Fim3 9 
within a population. 10 
Results 11 
Multiple fimbrial promoter variants within cultures 12 
From the 96 unassembled UK B. pertussis genome sequences, 2648 reads were matched exactly to 13 
one of the fim2 regular expressions in Table 1 or to one of the reverse complements thereof. After a 14 
second filter to eliminate false positives and uncertain matches, 2580 fim2 poly(C) tract±spanning 15 
reads were kept. The twice-filtered reads contained fim2 poly(C) tracts ranging in length from 6 to 16 
20 bp. Multiple fim2 poly(C) tract lengths were found within samples (Table 2), with a mean intra±17 
isolate range of 4.2 bp (standard deviation = 2.3 bp). The deoxythimidine residue that punctuates 18 
the fim2 poly(C) tract of B. pertussis Tohama was also found in UK001, UK002 and UK004 (58%, 19 
17% and 23% of reads respectively), and was counted as an internal deoxycytidine for the purpose 20 
of poly(C) tract length enumeration. Our numbering convention thus differs from that of Chen et al. 21 
(2010), who examined only T-punctuated fim2 poly(C) tracts, and whose enumeration excluded 22 
deocytidines on the 5 side of the punctuating deoxythymidine. 23 
9 
Using the equivalent double filter for fim3, 1914 reads were matched exactly by the first filter, and 1 
1660 fim3 poly(C) tract±spanning reads were kept after the second filter. The twice-filtered reads 2 
contained fim3 poly(C) tracts ranging in length from 6 to 20 bp. As with fim2, multiple poly(C) tract 3 
lengths were found within samples (Table 2), with a mean intra±isolate range of 5.2 bp (standard 4 
deviation = 3.0 bp). 5 
For fimX, 4463 reads were matched by the first filter, and 4381 fimX poly(C) tract±spanning reads 6 
were kept after the second filter. The fimX poly(C) tracts were less variable than those of the other 7 
two fimbrial genes (mean intra±isolate range = 1.1 bp, standard deviation = 0.4). In 77 of the 96 8 
genome-sequenced UK isolates, fimX poly(C) tracts did not exceed 7 bp in length. Isolate UK071 9 
contained a fimX poly(C) tract of 9 bp, the longest among the UK isolates. 10 
Read lengths for UK025 to UK100 were all 150 bp (average of 1.26 million reads per isolate, 11 
standard deviation = 0.26 million), whereas read lengths for other available B. pertussis Illumina 12 
sequences were 54 bp (average of 5.40 million reads per isolate for UK strains, standard deviation = 13 
1.66 million). For fim2 and fimX, poly(C) tract±spanning reads were more numerous in the genomes 14 
sequenced at 54 bp per reads, whereas for fim3, poly(C) tract±spanning reads were more numerous 15 
in the genomes sequenced at 150 bp per read (Table 3). Since a 54 bp read is less likely than a 150 16 
bp read to span a given sequence, the higher tally of fim2 and fimX poly(C) tracts in the 54 bp 17 
genome sequences can be attributed to the higher coverage of those genomes (71.4-fold versus 18 
46.1-fold for the 150 bp genome sequences). For fim3, the higher tally in the 150 bp genome 19 
sequences can be attributed to the broader size range of poly(C) tracts (N=JCA
¿Pu
 = 5.2 bp versus 20 
N=JCA
¿Pt
 = 4.2 bp), with the longer part of this range being more likely to be encompassed by 21 
longer reads. 22 
10 
After normalisation to genome coverage, the yields of fim2 and fim3 poly(C) tract±spanning read 1 
were higher from the 150 bp genomes than from the 54 bp genomes, but the yield for fimX stayed 2 
higher for the 54 bp genomes (Table 3, column 8). 3 
Presence of multiple serotypes within cultures 4 
In this study an aliquot of culture prepared for genome sequencing from strains UK025 to UK046 5 
was preserved by the addition of formaldehyde to 1 %. Individual bacteria in these preserved 6 
suspensions were analysed for expression of Fim2 and Fim3 using anti-Fim2 and anti-Fim3 7 
monoclonal antibodies and two-colour flow cytometry. The flow cytometry scatter plots obtained 8 
and the poly(C) tract lengths determined for each isolate are shown in Figure 1. In each of 22 9 
isolates examined by two-colour flow cytometry, B. pertussis cells of all four possible fimbrial 10 
serotypes Fim2íFim3í, Fim2íFim3+, Fim2+Fim3í and Fim2+Fim3+) were present (Fig. 1, 11 
scatterplots; Fig.2). One fimbrial serotype was dominant (>55 % of the population) in 21 out of the 12 
22 isolates (Figure 2). In isolate UK043, which had a bvgí colony morphology, Fim2íFim3í cells 13 
were dominant (89% of the population). FimX surface expression was not investigated owing to the 14 
lack of available antibodies. 15 
Gates were set so that the bacteria plus conjugate control was 99% enclosed inside the Fim2íFim3í 16 
quadrant. Although this may misidentify some events as Fim2íFim3í (for instance the lower portion 17 
of the Fim3+ cloud of UK042 in Figure 1), it does ensure that false positives are avoided. The 18 
diagonal streaking that can be seen in the Fim2+Fim3+ quadrant of some scatterplots (Fig. 1) is 19 
attributable to clumping of bacteria, with single bacteria towards the lower left and clumped 20 
bacteria towards the upper right. This analysis used a gate that excluded most clumped bacteria, but 21 
when a larger gate was used so as to include more clumped bacteria, the fraction of Fim2+ or Fim3+ 22 
bacteria remained very similar (data not plotted). Hence the results presented here are not dependent 23 
on the chosen flow cytometry analysis gate. 24 
11 
In all 22 of these isolates, the fim2 and fim3 promoter poly(C) tracts were present in the Illumina 1 
sequencing data as multiple variants. The broadest range for fim2 occurred in UK086, with poly(C) 2 
tract lengths ranging from 7 to 17. The broadest range for fim3 occurred in UK057, with poly(C) 3 
tract lengths ranging from 7 to 19. 4 
Relationship between median fimbrial poly(C) tract length and serotype 5 
Among the 21 bvg+ isolates studied by paired genome sequencing and two-colour flow cytometry, 6 
Fim2 median fluorescence was high in 8 phenotypically bvg+ isolates that had median fim2 poly(C) 7 
tracts lengths of 12 to 16 (Table 2). In the other 13 bvg+ isolates tested in this paired analysis, Fim2 8 
median fluorescence was at least 13-fold lower, and median poly(C) tract lengths were either 10 or 9 
11. fim2 median poly(C) tract lengths longer than 16 were not seen in the 22 isolates tested by flow 10 
cytometry but were seen in four of the other 74 UK isolates. 11 
Fim3 median fluorescence was high in 13 phenotypically bvg+ isolates that had median fim3 12 
poly(C) tracts lengths of 13 or 14. In the other 8 bvg+ isolates tested, Fim3 median fluorescence was 13 
at least 11-fold lower, and median fim3 poly(C) tract lengths were in the range 10 to 13. fim3 14 
median poly(C) tract lengths longer than 14 were not seen in the 22 isolates tested by flow 15 
cytometry but were seen in four of the other 74 UK isolates. 16 
In UK043, fim2 and fim3 median poly(C) tract lengths were 15 and 14 respectively, but median 17 
fluorescence was low for both Fim2 and Fim3 Over 70% of cells were Fim2íFim3í (Fig 2). This 18 
isolate had bvgí colony morphology, and this decoupling of surface expression from poly(C) tract 19 
length was therefore expected. It was, however, serotyped by agglutination as Fim3+. 20 
Among the other 74 sequenced UK isolates (which were not analysed by flow cytometry) UK015 21 
provided the sole example of a homogeneous fim2 promoter (38 Illumina reads spanning the fim2 22 
poly(C) tract, all with a poly(C) tract length of 9 nucleotides). The range of fim2 poly(C) tract 23 
12 
lengths in UK010 was not determined since only one spanning read was available. There were no 1 
unambiguous examples of homogenous fim3 promoters (only one spanning read was available for 2 
UK017). 3 
For Fim2 and Fim3, the relationships between promoter poly(C) tract lengths and expression are 4 
therefore as follows: a bvg+ population is Fim2+ if the median poly(C) tract length is > 11 (upper 5 
bound not established, but at least 16), and a bvg+ population is Fim3+ if the median poly(C) tract 6 
length is > 13 (upper bound not established, but at least 14). 7 
Optimal poly(C) tract lengths for B. pertussis fimbrial promoter activity have been proposed from 8 
observations made with luciferase reporter gene constructs (Chen et al., 2010). In nineteen of the 21 9 
bvg+ isolates described here, surface expression of Fim2 or Fim3 correlated with a majority of fim2 10 
or fim3 promoters having poly(C) tracts unambiguously in the proposed active range (Figure 1, 11 
shaded in bar charts). . However, the correlation broke down for two isolates. In UK037, the 12 
majority of fim2 poly(C) tracts were outside the proposed optimal range, but the majority of cells in  13 
this culture were Fim2+. Similarly, in UK044, the majority of fim3 poly(C) tracts were outside the 14 
proposed optimal range, while the majority of cells were Fim3+. 15 
Relationship between poly(C) tract length and serotype as determined by 16 
agglutination 17 
Serotypes determined by agglutination were not uniformly in agreement with poly(C) tract length 18 
distributions. Thirteen of the 96 genome-sequenced isolates (including UK043) had serotypes by 19 
agglutination that conflicted with the rules proposed above connecting median poly(C) tract length 20 
to expression (Table 4); and if upper bounds for ³DFWLYH´ median poly(C) tract lengths could be 21 
established, additional conflicting examples would probably be apparent. For 59 of the 96 isolates, 22 
serotypes by agglutination were in agreement with median poly(C) tract lengths. 23 
13 
Serotypes by agglutination were in agreement with the flow cytometric measurements of Fim2 and 1 
Fim3 for twenty of the 22 isolates that were analysed by flow cytometry (Table 2). The exceptions 2 
were UK030 (Fim2íFim3+ by agglutination, but 88% Fim2+Fim3í by flow cytometry) and the bvgí 3 
isolate UK043. Four of the 96 genome-sequenced UK isolates were serotyped as Fim2,3, and one 4 
was serotyped as Fimí, but these five were not included in the flow cytometric analysis 5 
(Supplementary Table S1: UK001, UK003, UK006, UK010 and UK068). 6 
Subpopulations with the potential to express FimX 7 
In 87 of the 96 UK isolates, all fimX poly(C) tracts were 8 bp or shorter, suggesting that these 8 
strains are FimXí. The longest fimX poly(C) tract found in a UK isolate was 9 bp, in UK024, which 9 
is shorter than the proposed optimum length for expression (Chen et al., 2010). 10 
Since no reagents are available to detect FimX protein, the possible existence of FimX+ 11 
subpopulations can be tested only by scanning genome sequences for fimX poly(C) tracts of 12 
plausibly transcription-permissive lengths. A further 275 unassembled B. pertussis genome 13 
sequences, all from non±United Kingdom isolates, were therefore filtered through the same script as 14 
was used for the 96 UK isolates. In each of 195 non-UK isolates, the longest observed fimX poly(C) 15 
tract length was 7 bp, and the longest fimX poly(C) tract lengths observed in the whole dataset were 16 
10 bp (found in two isolates), which is shorter than the proposed optimum length for expression. 17 
Discussion 18 
Fimbriae are required by B. pertussis for colonisation of the human respiratory tract; and we have 19 
shown in this study using two-colour flow cytometry, that individual cultures each contain cells of 20 
more than one fimbrial serotype. In the same cultures, we have detected multiple variants of the 21 
promoters for each of the serologically distinct fimbrial major subunits. This study therefore 22 
provides cellular and genomic corroboration for the suggestion by Heikkenen et al. (2008), and 23 
14 
recently reported serological evidence, that B. pertussis expresses Fim2 and Fim3 during infection 1 
irrespective of the predominant serotype of case isolates (Hallander et al., 2013). 2 
The intra±culture serotype heterogeneity described here reflects the intrinsic susceptibility of 3 
repetitive DNA elements (in this case, promoter poly(C) tracts) to slipped-strand mispairing during 4 
DNA replication. The steric feasibility of bulge defects in the base-pairing of nucleic acids was 5 
demonstrated more than 50 years ago, and the formation of such defects by slipped-strand 6 
mispairing was postulated immediately as a mechanism for point mutations in DNA regions of low 7 
complexity (Fresco & Alberts, 1960). Insertions and deletions within runs of short (1 to 10 bp) 8 
repeated elements have subsequently been observed in human genetic disorders and in antigenic 9 
switching by pathogens (reviewed by van der Woude & Bäumler, 2004) 6SRUDGLF+XQWLQJGRQ¶V10 
disease arises from expansion of a run of sequential CAG glutamine codons in the HTT gene 11 
(Myers et al., 1993), and similar CAG expansions are seen in several other neurodegenerative 12 
disorders. Analogous in-frame trinucleotide repeats (AGT or TCT) occur in the MgPa adhesin 13 
operon of Mycoplasma genitalium, and variations in the number of repeat units have been observed 14 
within and between isolates (Ma et al., 2012). The opacity genes of Neisseria gonorrhoeae are 15 
subject to reversible frameshifts, at a rate of 10í4±10í3/cell/generation, resulting from changes in the 16 
number of copies of a CTCTT repeat in the signal peptide±encoding sequence (Murphy et al., 17 
1989). Variation in the number of copies of a TAAA repeat in the nadA promoter of Neisseria 18 
meningitidis MC58 leads to colonies with differential NadA expression appearing on the same 19 
culture plate (Martin et al., 2003). 20 
The simplest possible repeat elements, homopolymeric tracts, account for many reported instances 21 
of slipped-strand mispairing in bacteria. There are 5684 homopolymeric tracts longer than 4 bp in 22 
the B. pertussis Tohama I genome sequence (Parkhill et al., 2003), of which 78% are 5 bp in length. 23 
The 6 bp homopolymeric tracts account for 15% of the total, and frequency decreases with 24 
15 
increasing length. In a survey of expected versus observed homopolymeric tract frequencies in 139 1 
sequenced bacterial genomes, B. pertussis was ranked twelfth lowest with an expected/observed 2 
ratio of 0.23 (Coenye & Vandamme, 2005), and most reports of homopolymeric tract±associated 3 
antigenic variation are from bacteria with higher expected/observed ratios (for instance, 2.1 in 4 
Neisseria meningitidis and 3.5 in Helicobacter pylori). It is therefore striking that the earliest report 5 
of B. pertussis slipped-strand mispairing was in the bvgS gene, where the impact is magnified by 6 
pleiotropy. Stibitz et al. (1989) found that bvgí strains arose by frameshifting expansion of a C6 7 
tract at bvgS codons 1103±4, and that the frequency of the bvg+/í switch varied between two strains. 8 
Transcription from the fimbrial promoters requires that their poly(C) tracts be longer (Chen et al., 9 
2010) than the footprints of some DNA polymerases (Beese et al., 1993; Eom et al., 1996), so the 10 
heterogeneity of fimbrial promoters reported here is perhaps unsurprising. Fazekas et al. (2010) 11 
were able to improve the fidelity of PCR amplification across homopolymeric tracts by using PCR 12 
enzymes with extended DNA-binding footprints. Compared to a 68°C PCR extension, DNA 13 
replication in B. pertussis should be less vulnerable to slipped-strand mispairing because the 3 end 14 
of the nascent strand is less likely to dissociate at physiological temperatures. Nevertheless, the 15 
imperfect fidelity of C6 replication in bvgS, along with the apparent selection against 16 
homopolymeric tracts throughout the genome, suggests that B. pertussis is unable to replicate 17 
homopolymeric tracts with high fidelity if they are longer than 5 bp. The fimbrial poly(C) tracts of 18 
B. pertussis, being several nucleotides longer, are directly analogous to the poly(C) tract of opc 19 
(Sarkari et al., 1994) and the poly(G) tract of porA (van der Ende et al., 1995; Tauseef et al., 2013), 20 
both in N. meningitidis. In each of these examples, expression of a surface antigen is modulated by 21 
frequent and apparently stochastic changes in the spacing between the í35 and í10 promoter 22 
regions. 23 
16 
In an organism that uses slipped-strand mispairing to effect antigenic variation, cell division must, 1 
at least some of the time, result in daughter cells inheriting surface antigens that they are unable to 2 
express anew. The correlation between fimbrial poly(C) tract length distribution and surface 3 
expression is therefore likely to be imperfect, especially if antigenic variation is rapid. This may be 4 
exemplified in the present study by the two isolates with poly(C) tracts lengths predominantly 5 
outside the transcription-permissive range estimated by Chen et al. (2010); though an alternative 6 
explanation might be that the estimates of transcription-permissive lengths were compromised by 7 
slipped-strand mispairing in the reporter gene constructs used. In this study, we obtained statistical 8 
estimates of transcription-permissive fimbrial poly(C) tract lengths, as distinct from the previous 9 
reporter gene±based estimates, but isolates with conflicting serotype (by agglutination assay) were 10 
still apparent (Table 4). However, the objective of the present study was not to determine precise 11 
limits for promoter activity, and the range of poly(C) tract lengths in individual cultures was broad 12 
enough to encompass the multiple serotypes seen in the same cultures (Figure 1). 13 
The major impediment to estimating in vivo poly(C) tract diversity lies in the potential for 14 
laboratory DNA polymerases to add to the diversity in vitro. In our hands, B. pertussis fimbrial 15 
poly(C) tracts can be sequenced successfully using dideoxy chemistry if they are amplified in 16 
Escherichia coli as plasmid inserts, implying correct amplification by the E. coli DNA polymerase. 17 
However, when PCR-amplified fimbrial promoters are sequenced without cloning, multiple 18 
superimposed traces appear on the downstream side of the poly(C) tract, representing multiple 19 
poly(C) tract lengths of which some might represent slipped-stranded mispairing in the PCR tube 20 
rather than in the organism. For the present study, we sought to avoid PCR-generated diversity by 21 
using high coverage sequence data. The 10-cycle amplification in the Kapa HiFi library 22 
amplification protocol amounts to 10000-fold less amplification that takes place in a 30-cycle PCR 23 
reaction, so the number of in vitro-generated poly(C) tract lengths is likely to be minimal. In 24 
17 
addition, only a few of the poly(C) tract length distributions in Figure 1 resemble the bell-shaped 1 
distribution that would be expected for purely PCR-generated diversity. 2 
The distribution of B. pertussis fimbrial serotypes, as determined by agglutination, has varied 3 
between countries and over time, and may have been influenced by differing vaccination policies 4 
(reviewed by Poolman & Hallander, 2007). Our data indicate that the result returned by an 5 
agglutination assay is the serotype of the largest subpopulation in the sample being assayed; so the 6 
fact that temporal and geographical trends can be discerned at all suggests that B. pertussis 7 
populations are stably diverse, with selective pressure being required to displace a dominant 8 
serotype. Detection limits for current serotyping assays are not known, but could be determined 9 
with blended samples following separate flow cytometric analyses. The proportion of United 10 
Kingdom isolates with serotype Fim2+ (by agglutination) dropped sharply from 47 % (n = 110) in 11 
1988 to 2001, to 3 % (n = 184) in 2002 to 2004, and 2 % (n = 166) in 2005 to 2008, after the 12 
introduction of aP vaccines (a preschool booster in 2001 and a replacement for the previous wP 13 
given at 2, 3 and 4 months in 2004 (Litt et al., 2009), but increased in 2011±2012 (Alexander et al., 14 
2012) to levels comparable with the pre-vaccine and whole-cell vaccine eras. It is possible that 15 
population immunity to the predominant serotype builds up until a tipping point is reached and the 16 
expression of the alternative serotype is favoured. However, there is no clear pattern in the median 17 
poly(C) tract lengths over these periods, partly because of a sampling bias in favour of 2012 isolates 18 
(Figure S1 supplementary materials). 19 
FimX is 73% similar to Fim2 and 70% similar to Fim3, but has been detected only by mass 20 
spectrometry and only in one B. pertussis isolate (Tefon et al., 2011). No laboratory antibodies are 21 
available for more rapid detection, and the capacity of FimX to substitute for Fim2 and Fim3 is 22 
unknown. Most of the fimX poly(C) tracts counted in the present study were 6 to 8 bp long, which is 23 
probably too short to allow transcriptional initiation. The emergence of a FimX+ strain from one 24 
18 
with exclusively short fimX poly(C) tracts might conceivably start with a low-probability DNA 1 
replication error followed by increasingly probable recurrences as the poly(C) tract grew further 2 
beyond the size of the DNA polymerase footprint in successive generations. The analogous 3 
phenomenon in human CAG expansion disorders, where successive generations are at increased 4 
risk as their CAG repeats expand, is termed genetic anticipation (Walker, 2007). The 10 bp fimX 5 
poly(C) tracts found in two strains are comparable in length to some of the fim2 and fim3 poly(C) 6 
tracts (Figure 1); but a robust investigation of FimX genetic anticipation requires more data than 7 
were available in the genome sequences (Table 3 column 4), and would be better accomplished by 8 
generating specific antibodies and using them in flow cytometry. 9 
Thus, in this study we have characterised the distribution of poly(C) tract lengths in the promoters 10 
of fim2 and fim3 and shown that cultures contain multiple sub-populations with differing poly(C) 11 
lengths. For a subset of strains, we determined expression of Fim2 and Fim3 on each bacterium 12 
using two-colour flow cytometry, and showed that whilst there is a predominant serotype in each 13 
culture, multiple combinations of Fim2 and Fim3 expression occur in a single culture. The optimal 14 
poly(C) tract lengths for expression of Fim2 and Fim3 were greater than 11 bp or 13 bp respectively 15 
for most strains, but for 13 out of 96 strains the observed serotype conflicted with that predicted by 16 
median poly(C) tract length (Table 4). This demonstrates that expression of Fim2 and Fim3 is more 17 
fluid than previously though and confirms the serological evidence that B. pertussis expresses both 18 
Fim2 and Fim3 in vivo. It is therefore important for B. pertussis vaccines that rely on protection 19 
mediated by fimbriae to elicit antibodies against both fimbrial antigens. 20 
19 
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Tables 1 
Table 1 2 
Gene  Regular expression 
fim2 (1)       gccc[ct]c\{2,17\}taagacc 
 (2) gaatcagccc[ct]c\{2,17\}t 
   
fim3 (1)        gc\{6,20\}ggacctg 
 (2)  ccatcagc\{6,20\}gg 
 (3) accatcagc\{6,20\}g 
   
fimX (1)        gc\{6,20\}gaggcgt 
 (2)  ccatcagc\{6,20\}ga 
 (3) tccatcagc\{6,20\}g 
Table 1. Patterns used in the first of two sequential text filters to identify genome sequence reads 3 
spanning the promoter poly(C) tracts of fim2, fim3 or fimX. The patterns are printed in ED regular 4 
expression syntax (Thompson & Ritchie, 1971). The reverse-complement of each pattern was also 5 
used. 6 
24 
Table 2 1 
    Fim2  Fim3 
























UK025 2008 Fim3 ERS176852 33 10 3 (9 to 11) 4.6   8 14 6 (13 to 18) 320.2 
UK026 2008 Fim3 ERS176853 28 10 2 (10 to 11) 4.3  12 14 3 (13 to 15) 251.4 
UK027 2008 Fim3 ERS176854 24 10 3 (9 to 11) 4.6  15 14 4 (12 to 15) 335.3 
UK028 2009 Fim3 ERS176855 27 10 3 (9 to 11) 4.6  10 14 4 (12 to 15) 360.7 
UK029 2009 Fim2 ERS176856 6 16 4 (14 to 17) 708.8  20 13 5 (11 to 15) 12.8 
UK030 2011 Fim3 ERS176857 4 16 3 (15 to 17) 703.3  26 10 3 (9 to 11) 8.1 
UK031 2011 Fim2 ERS176858 9 15 4 (13 to 16) 666.5  24 10 3 (9 to 11) 8.1 
UK032 2011 Fim3 ERS176859 39 11 3 (10 to 12) 4.6  22 14 8 (12 to 19) 209.8 
UK033 2011 Fim3 ERS176860 30 10 2 (9 to 10) 4.6  5 14 2 (14 to 15) 246.7 
UK034 2011 Fim2 ERS176861 6 15 4 (13 to 16) 608.7  20 11 3 (10 to 12) 9.3 
UK035 2012 Fim2 ERS176862 11 15 7 (11 to 17) 361  21 12 3 (11 to 13) 12 
UK036 2012 Fim3 ERS176863 31 10 3 (9 to 11) 4.1  6 14 2 (13 to 14) 666.5 
UK037 2012 Fim2 ERS176864 12 14 6 (11 to 16) 255.8  38 10 3 (9 to 11) 9.9 
UK038 2012 Fim3 ERS176865 30 10 3 (9 to 11) 4.9  17 14 8 (12 to 19) 394.6 
UK039 2012 Fim3 ERS176866 28 10 2 (9 to 10) 4.6  11 14 9 (12 to 20) 341.5 
UK040 2012 Fim2 ERS176867 11 15 7 (13 to 19) 270  37 12 8 (11 to 18) 9.9 
UK041 2012 Fim2 ERS176868 7 15 5 (13 to 17) 270.2  27 12 5 (11 to 15) 9.6 
UK042 2012 Fim3 ERS176869 28 10 2 (10 to 11) 4.7  6 14 3 (12 to 14) 178.3 
UK043 2012 Fim3 ERS176870 11 15 8 (9 to 16) 4.6  11 14 3 (13 to 15) 15.3 
UK044 2012 Fim3 ERS176871 36 10 3 (9 to 11) 4.5  6 13.5 8 (11 to 18) 291 
UK045 2012 Fim3 ERS176872 35 10 3 (10 to 12) 4.2  5 14 3 (13 to 15) 312.8 
UK046 2012 Fim3 ERS176873 43 10 4 (9 to 12) 4  9 14 6 (12 to 17) 191.9 
Table 2. Promoter poly(C) tract lengths and surface expression of Fim2 and Fim3 in B. pertussis isolates UK025 to UK046. ENA identifiers are 2 
European Nucleotide Archive sample names. Serotype by agglutination uses the nomenclature of Hallander et al. (2005). Each isolate was cultured 3 
twice: once for serotyping by agglutination and once for the other two analyses, with cultures being split between flow cytometry and whole genome 4 
sequencing. Values (apart from fluorescence) for the other 74 UK isolates are in Table S3 (supplementary materials). 5 
6 
25 
Table 3 1 
Isolates Read 
length 
No. of reads Genome coverage No. of reads spanning poly(C) tracts   Yield of reads spanning poly(C) tract Gene 
    1st filter 2nd filter  1st filter 2nd filter  
UK001 to UK024 
(20 isolates) 
54 5401318 (1704184) 71.4-fold (22.5-fold) 33.95 (33.30) 32.70 (32.56)   45.91% (40.75%) 44.22% (39.73%) fim2 
   18.50 (15.40) 15.10 (14.14)  24.93% (18.72%) 15.10 (14.14) fim3 
   80.15 (33.26) 79.40 (32.98)  109.70% (21.94%) 108.66% (22.04%) fimX 
          
UK025 to UK100 
(76 isolates) 
150 1255255 (259298) 46.1-fold (9.5-fold) 25.91 (16.18) 25.34 (16.12)  56.71% (33.85%) 55.45% (33.80%) fim2 
   20.32 (14.25) 17.87 (13.83)  43.56% (26.83%) 38.25% (25.89%) fim3 
   37.63 (11.54) 36.75 (11.26)  81.30% (16.52%) 79.46% (16.47%) fimX 
Table 3. Availability of Illumina reads spanning the fimbrial poly(C) tracts in B. pertussis isolates UK001 to UK024 and UK025 to UK100. All values 2 
other than read length are arithmetic means per isolate (standard deviations italicised). Yields are expressed as percentages of genome coverage. 3 
Genome sequences were not available for UK007, UK012, UK013 and UK019. 4 
26 
Table 4 1 
Isolate   Serotype  Median poly(C) tract length 
   Observed Predicted   fim2 fim3 
UK001   Fim Fim2   14 9 
UK003  Fim2,3 Fim2  16 6 
UK005  Fim3 Fim2  17 13 
UK010  Fim2,3 Fim2  17 10.5 
UK011  Fim3 Fim2  14 13 
UK015  Fim3 Fim  9 10.5 
UK030  Fim3 Fim2  16 10 
UK043  Fim3 Fim2,3  15 14 
UK051  Fim3 Fim2  12 13 
UK061  Fim3 Fim  11 8 
UK064  Fim3 Fim2,3  14 14 
UK072  Fim3 Fim2  12 13 
UK081  Fim3 Fim2  16 9 
Table 4. B. pertussis isolates with serotype by agglutination conflicting with serotype 2 
predicted from fim2 and fim3 median poly(C) tract length. Observed, by agglutination; 3 
Predicted, from median poly(C) tract lengths. Serotype nomenclature is as described by 4 
Hallander et al. (2005). Discrepant fimbrial serotypes between those observed and predicted 5 
are emboldened.  6 
27 
Figure legends 1 
Figure 1. Bar charts: distribution of fim2 and fim3 promoter poly(C) tract lengths in 2 
unassembled genome sequencing reads for 22 United Kingdom isolates of B. pertussis. 3 
Scatterplots: surface expression of Fim2 and Fim3 in aliquots of the same cultures as were 4 
used for the genome sequencing, determined by two-colour flow cytometry. The dominant 5 
serotype by agglutination in each sample is stated in parentheses in the bar chart titles. Shaded 6 
bars indicate poly(C) tract lengths that were previously reported to be transcription-permissive 7 
(Chen et al., 2010). fim2 poly(C) tract lengths include the C residues that precede the T 8 
residue that interrupts sequences analysed by Chen et al. The particles on the outside bounds 9 
of the scatterplots are those with a very high fluorescence that exceeds the dynamic range of 10 
the flow cytometer: they are more likely to be clumps of AlexaFluor-conjugated antibody than 11 
to be bacteria. 12 
Figure 2. Relative abundances of four fimbrial serotype permutations in individual cultures of 13 
22 UK isolates of B. pertussis analysed by two-colour flow cytometry. 14 
27
Figure 1 (part 1 of 5)
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Figure S1 Median poly(C) tract lengths of B. pertussis isolates
UK001 to UK048, isolated from 1920 to 2012.
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Table S2 (continued) Unassembled genome sequence ﬁles for non–United Kingdom isolates referred


























UK001 1920 1 ERS018345 80 14 4 (12 to 15) nd 46 9 4 (7 to 10) nd
UK002 1942 1,2 ERS018346 30 16 10 (8 to 17) nd 22 13 5 (12 to 16) nd
UK003 1946 1,2,3 ERS018347 18 16 3 (15 to 17) nd 0 nd nd nd
UK004 1947 1,2 ERS018348 22 15.5 2 (15 to 16) nd 35 10 3 (9 to 11) nd
UK005 1949 1,3 ERS018349 11 17 7 (14 to 20) nd 13 13 9 (11 to 19) nd
UK006 1967 1,2,3 ERS018350 5 14 2 (14 to 15) nd 5 14 7 (13 to 19) nd
UK008 1979 1,2 ERS018349 6 16 4 (15 to 18) nd 19 13 9 (11 to 19) nd
UK009 1982 1,2 ERS018350 6 15 5 (12 to 16) nd 4 12.5 5 (9 to 13) nd
UK010 1982 1,2,3 ERS018353 1 17 1 (17 to 17) nd 1 15 1 (15 to 15) nd
UK011 1983 1,3 ERS018354 12 14 8 (11 to 18) nd 2 16.5 8 (13 to 20) nd
UK014 1998 1,2 ERS018355 16 17 10 (8 to 17) nd 23 9 1 (9 to 9) nd
UK015 2002 1,3 ERS018356 38 9 1 (9 to 9) nd 1 14 1 (14 to 14) nd
UK016 2006 1,2 ERS018357 20 17 3 (15 to 17) nd 27 9 4 (7 to 10) nd
UK017 2007 1,3 ERS018358 66 10 6 (6 to 11) nd 1 14 1 (14 to 14) nd
UK018 2010 1,3 ERS018359 37 10 2 (9 to 10) nd 7 19 7 (14 to 20) nd
UK020 2009 1,3 ERS018360 83 9 2 (9 to 10) nd 5 15 4 (13 to 16) nd
UK021 2010 1,2 ERS018361 5 14 4 (13 to 16) nd 34 12 3 (11 to 13) nd
UK022 2010 1,2 ERS018362 7 15 5 (12 to 16) nd 35 11 3 (10 to 12) nd
UK023 2010 1,3 ERS018363 92 10 3 (9 to 11) nd 11 15 9 (12 to 20) nd
UK024 2010 1,3 ERS018364 99 10 3 (9 to 11) nd 11 15 8 (13 to 20) nd
UK049 2012 1,3 ERS227750 51 10 3 (9 to 11) nd 2 15 3 (14 to 16) nd
UK050 2012 1,2 ERS227751 15 16 6 (13 to 18) nd 21 10 3 (9 to 11) nd
UK051 2011 1,3 ERS227752 48 12 3 (11 to 13) nd 6 13 3 (12 to 14) nd
UK052 2011 1,2 ERS227753 6 13.5 6 (10 to 15) nd 22 11 3 (10 to 12) nd
UK053 2011 1,3 ERS227754 37 10 3 (9 to 11) nd 5 14 3 (13 to 15) nd
UK054 2011 1,3 ERS227755 18 10 2 (10 to 11) nd 3 14 2 (13 to 14) nd
UK055 2012 1,2 ERS227756 8 16.5 7 (12 to 18) nd 31 10 3 (9 to 11) nd
UK056 2012 1,2 ERS227757 15 14 4 (12 to 15) nd 15 10 2 (9 to 10) nd
UK057 2012 1,3 ERS227758 48 9 2 (8 to 9) nd 5 15 13 (7 to 19) nd
UK058 2012 1,2 ERS227759 12 15 7 (12 to 18) nd 14 12 3 (11 to 13) nd
UK059 2012 1,3 ERS227760 63 10 3 (9 to 11) nd 12 14.5 8 (12 to 19) nd
UK060 2012 1,2 ERS227761 9 16 4 (13 to 16) nd 18 12 4 (10 to 13) nd
UK061 2012 1,3 ERS227762 36 11 3 (10 to 12) nd 2 11 9 (7 to 15) nd
UK062 2012 1,2 ERS227763 9 15 5 (13 to 17) nd 19 11 4 (10 to 13) nd
UK063 2012 1,3 ERS227764 45 10 2 (9 to 10) nd 5 13 5 (11 to 15) nd
UK064 2012 1,3 ERS227765 27 14 8 (9 to 16) nd 9 15 7 (13 to 19) nd
UK065 2012 1,3 ERS227766 62 10 4 (8 to 11) nd 12 14 8 (13 to 20) nd
UK066 2012 1,3 ERS227767 50 9 2 (9 to 10) nd 14 13 6 (11 to 16) nd
UK067 2012 1,2 ERS227768 9 15 3 (14 to 16) nd 33 12 4 (10 to 13) nd
UK068 2012 1,2,3 ERS227769 13 15 8 (9 to 16) nd 11 14 7 (14 to 20) nd
UK069 2012 1,3 ERS227770 41 11 4 (9 to 12) nd 11 13 2 (13 to 14) nd
UK070 2012 1,3 ERS227771 42 11 4 (10 to 13) nd 16 13 7 (9 to 15) nd
UK071 2012 1,2 ERS227772 7 14 8 (9 to 16) nd 12 13 3 (12 to 14) nd
UK072 2012 1,3 ERS227773 39 12 4 (10 to 13) nd 14 13.5 3 (13 to 15) nd
UK073 2012 1,2 ERS227774 14 15 7 (12 to 18) nd 19 12 3 (11 to 13) nd
UK074 2012 1,3 ERS227775 45 9 3 (8 to 10) nd 11 14 9 (11 to 19) nd
UK075 2012 1,3 ERS227776 44 10 2 (9 to 10) nd 11 14 7 (11 to 17) nd
UK076 2012 1,2 ERS227777 10 15 6 (12 to 17) nd 53 12 12 (7 to 18) nd
UK077 2012 1,3 ERS227778 53 10 3 (9 to 11) nd 15 14 3 (13 to 15) nd
UK078 2012 1,2 ERS227779 12 15.5 5 (12 to 16) nd 38 12 11 (10 to 20) nd
UK079 2012 1,2 ERS227780 14 14.5 5 (12 to 16) nd 29 12 4 (11 to 14) nd
UK080 2012 1,3 ERS227781 33 9 1 (9 to 9) nd 8 14.5 10 (6 to 15) nd
UK081 2012 1,3 ERS227782 13 16 5 (13 to 17) nd 81 9 3 (8 to 10) nd
UK082 2012 1,3 ERS227783 41 10 3 (9 to 11) nd 11 14 10 (6 to 15) nd
UK083 2012 1,2 ERS227784 9 16 3 (15 to 17) nd 51 11 4 (9 to 12) nd
UK084 2012 1,2 ERS227785 7 15 4 (13 to 16) nd 34 10 3 (9 to 11) nd
UK085 2012 1,3 ERS227786 44 10 5 (7 to 11) nd 9 14 8 (13 to 20) nd
UK086 2012 1,2 ERS227787 9 16 11 (7 to 17) nd 26 10 3 (9 to 11) nd
UK087 2012 1,3 ERS227788 37 9 3 (8 to 10) nd 12 14 4 (12 to 15) nd
UK088 2012 1,3 ERS227789 29 9 3 (8 to 10) nd 5 14 3 (13 to 15) nd
UK089 2012 1,3 ERS227790 35 10 4 (9 to 12) nd 16 14 4 (12 to 15) nd
UK090 2012 1,3 ERS227791 27 10 3 (9 to 11) nd 12 14 5 (13 to 17) nd
UK091 2012 1,3 ERS227792 29 11 3 (10 to 12) nd 5 15 4 (13 to 16) nd
UK092 2012 1,2 ERS227793 11 15 11 (6 to 16) nd 41 11 4 (10 to 13) nd
UK093 2012 1,3 ERS227794 33 10 3 (9 to 11) nd 10 15 10 (7 to 16) nd
UK094 2012 1,2 ERS227795 4 16 3 (14 to 16) nd 47 10 3 (9 to 11) nd
UK095 2012 1,3 ERS227796 47 10 3 (9 to 11) nd 16 14 13 (6 to 18) nd
UK096 2012 1,2 ERS227797 4 7.5 3 (6 to 8) nd 0 nd nd nd
UK097 2012 1,3 ERS227798 41 10 3 (9 to 11) nd 21 14 7 (10 to 16) nd
UK098 2012 1,3 ERS227799 24 10 3 (9 to 11) nd 14 14 13 (6 to 18) nd
UK099 2012 1,2 ERS227800 9 14 11 (6 to 16) nd 27 11 5 (9 to 13) nd
UK100 2012 1,3 ERS227801 38 10 2 (10 to 11) nd 10 14 4 (12 to 15) nd
Table S3 Promoter poly(C) tract lengths of ﬁm2 & ﬁm3, and serotypes by agglutination, of B. pertussis isolates UK001 to UK024 and UK049 to UK100. ENA identiﬁers
are European Nucleotide Archive sample names. Serotype by agglutination uses the nomenclature of Robinson et al. (1989b). Surface ﬂuorescence was not determined
(nd). Values (including ﬂuorescence) for the other 22 UK isolates are in Table 2.
